Fibrostenosis Focused Therapeutics - RFP
The Crohn's and Colitis Foundation's Fibrostenosis Focused Therapeutics RFP funds translational research into novel, non-surgical therapies targeting fibrosis in IBD.
Funder: Crohn's and Colitis Foundation
Due Dates: June 30, 2026 (Letter of Intent) | August 14, 2026 (Full proposal)
Funding Amounts: Up to $450,000 for one year; renewals possible if milestones are achieved; indirect costs capped at 10%.
Summary: Supports innovative product development for treating fibrosis in IBD, with a focus on non-surgical solutions to fibrostenosis.
Key Information: Invitation is required to submit a full proposal; both companies and academic groups with commercialization focus are eligible.
Description
This funding opportunity from the Crohn's and Colitis Foundation aims to accelerate the development of novel, non-surgical therapies for fibrosis in inflammatory bowel disease (IBD), specifically targeting fibrotic strictures (fibrostenosis) in Crohn’s disease and ulcerative colitis. The program is designed for companies and academic groups associated with drug discovery centers, prioritizing projects rooted in clinical observations or published human IBD evidence. Proposals of special interest include those evaluating the therapeutic potential of modulating specific fibrotic pathways or employing multidisciplinary approaches. The overarching goal is to address the urgent, unmet need for effective, non-surgical interventions for fibrostenosis in IBD patients.
